معرفی
Ida Alanko is a Researcher at Åbo Akademi University's Faculty of Natural Sciences and Technology, Department of Pharmacy. Her work focuses on pharmaceutical sciences with particular emphasis on drug discovery, antimicrobial resistance, and molecular interactions between pathogens and host systems. She contributes significantly to research addressing global health challenges, particularly those related to the UN Sustainable Development Goals.
Alanko's research expertise spans multiple critical areas of pharmaceutical sciences. Her fingerprint reveals deep engagement with topics including Zika Virus, NS2B-NS3 protease inhibitors, staphylococcal superantigen-like proteins (SSL5), and immune evasion mechanisms involving Gelatinase B (MMP9) and phagocytosis. Her work bridges computational approaches with experimental validation in drug development.
Her publication record demonstrates consistent productivity with significant contributions across multiple high-impact journals. Analysis of her research trajectory shows an evolution from fundamental biochemical investigations of bacterial pathogenesis to sophisticated computational drug discovery approaches targeting viral and bacterial threats. Her work spans both antibacterial and antiviral research domains, with particular focus on combating drug-resistant pathogens.
Alanko has contributed to highly cited collaborative work, including the 2020 review on Molecular Dynamics Simulations which has garnered nearly 400 citations and been referenced in patents. Her research has attracted attention across academic and professional networks, with hundreds of readers on platforms like Mendeley and mentions across social media.
Her collaborative network spans multiple institutions and countries, with significant research partnerships evident in her co-authorship patterns. She works within interdisciplinary teams that combine expertise in microbiology, biochemistry, computational modeling, and pharmaceutical development to address complex health challenges.
